Wempredsol Injection contains Methylprednisolone 40mg, a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties. It is indicated for the management of various inflammatory, allergic, and autoimmune conditions including severe asthma exacerbations, rheumatoid arthritis, systemic lupus erythematosus, and acute exacerbations of multiple sclerosis. Wempredsol acts by modulating the immune response, reducing inflammation through inhibition of leukocyte infiltration, suppression of cytokine production, and stabilization of lysosomal membranes. This injectable formulation allows for rapid onset of action, making it suitable for acute and severe presentations where oral administration is not feasible. The dosage and duration of therapy should be individualized based on the severity of the condition and patient response, with careful monitoring to minimize potential adverse effects such as hyperglycemia, hypertension, osteoporosis, and increased susceptibility to infections. Contraindications include systemic fungal infections and known hypersensitivity to corticosteroids. Caution is advised in patients with diabetes mellitus, hypertension, peptic ulcer disease, and psychiatric disorders. Wempredsol Injection should be administered under strict medical supervision, ensuring adherence to recommended dosing regimens to optimize therapeutic outcomes while minimizing risks associated with corticosteroid therapy.